Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) Tax Provisions (2018 - 2024)

BioNexus Gene Lab's Tax Provisions history spans 7 years, with the latest figure at -$80701.0 for Q4 2024.

  • For Q4 2024, Tax Provisions rose 17.6% year-over-year to -$80701.0; the TTM value through Sep 2025 reached -$80701.0, down 189.24%, while the annual FY2024 figure was -$3494.0, 83.77% up from the prior year.
  • Tax Provisions for Q4 2024 was -$80701.0 at BioNexus Gene Lab, down from $152859.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $171488.0 in Q4 2020 and bottomed at -$97944.0 in Q4 2023.
  • The 5-year median for Tax Provisions is $10114.0 (2022), against an average of $24775.2.
  • The largest annual shift saw Tax Provisions skyrocketed 22134.09% in 2021 before it tumbled 211.83% in 2023.
  • A 5-year view of Tax Provisions shows it stood at $171488.0 in 2020, then plummeted by 52.71% to $81098.0 in 2021, then crashed by 192.61% to -$75102.0 in 2022, then crashed by 30.41% to -$97944.0 in 2023, then increased by 17.6% to -$80701.0 in 2024.
  • Per Business Quant, the three most recent readings for BGLC's Tax Provisions are -$80701.0 (Q4 2024), $152859.0 (Q3 2024), and $55584.0 (Q2 2024).